Bipartite gene expression systems offer fine spatial and temporal control of gene expression, and are crucial for dissecting gene function. The GAL4-UAS system, which has proven highly useful in *Drosophila*^[@R1]^, uses the *Saccharomyces cerevisiae* Gal4p protein, comprising a DNA-binding domain (DBD) and a transcriptional activation domain (AD). Gal4p homodimers bind a 17-nucleotide upstream activating sequence (UAS), resulting in transcription of a downstream gene^[@R2]^. Cell-specific promoters placed upstream of *GAL4* constitute a 'driver' construct, while UAS sites placed upstream of the gene of interest constitute an 'effector' construct. Incorporation of these constructs into separate transgenics creates standardized driver and effector lines, which can be crossed together, generating progeny with desired expression patterns ([Fig. 1a](#F1){ref-type="fig"}).

The bipartite nature of GAL4-UAS offers three major advantages over direct promoter-gene fusions. Large numbers of strains can be easily generated by crossing drivers and effector lines. Incorporating novel components into pre-existing driver and effector libraries requires minimal effort. Verified driver and effector strains become community reagents that foster experimental consistency and reproducibility. However, the GAL4-UAS system has not been successfully adapted for *C. elegans*. We optimized three components of the GAL4-UAS system to make it functional for *C. elegans* across 15--25°C, and demonstrated its robustness for tissue-specific gene expression, site-specific genetic rescue, and channelrhodopsin experiments.

Previous unpublished attempts using *S. cerevisiae* Gal4p DBD (residues 1--147, henceforth termed GAL4~SC~) with human herpes virus activation domain (VP16)^[@R3]^ as the driver components had poor performance in *C. elegans*. Since stronger activation domains improve performance of the GAL4 driver^[@R4]^, we tested VP64^[@R5]^, which has four tandem copies of VP16. We fused GAL4~SC~ to VP16 and VP64 and placed them both under the pharyngeal muscle promoter (*Pmyo-2*), designating them *Pmyo-2::GAL4~SC~::VP16* and *Pmyo-2::GAL4~SC~::VP64*, respectively. Comparing their performance in a *15xUAS::gfp* effector transgene strain (*syIs300)*, the *Pmyo-2::GAL4~SC~::VP64* driver yielded seven-fold more GFP fluorescence in pharyngeal muscles at room temperature ([Fig. 1b--c](#F1){ref-type="fig"}). The fluorescence observed requires both driver and effector transgenes ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). We therefore adopted VP64 as our activation domain.

We optimized UAS copy number by comparing constructs with 5×, 10×, 15×, and 20× copies of UAS upstream of *gfp* at equal concentrations in a strain with a *Pmyo-2::GAL4~SC~::VP64* driver (*syIs301*). We found successively increasing GFP fluorescence until 15xUAS copies (\~2.3 fold versus 5xUAS, p\<0.0001; \~1.3 fold vs. 10xUAS, p\<0.01, One-way ANOVA, Tukey's post-test), beyond which it appeared to saturate (\~1.1 fold versus 20xUAS, p=0.5, One-way ANOVA, Tukey's post-test; [Fig. 1d--e](#F1){ref-type="fig"}). Thus, 15xUAS was adopted for effector constructs.

To determine the robustness of our GAL4-UAS system under standard *C. elegans* growth temperatures (15--25°C), we assayed our *Pmyo-2::GAL4~SC~::VP64* driver and *15xUAS::gfp* effector combination, and found its transcriptional efficacy depended heavily on temperature, performing well only at 25°C ([Fig. 2b--c](#F2){ref-type="fig"}; \~67% drop at 20°C, \~80% drop at 15°C, p\<0.0001, Two-way ANOVA with Tukey's correction), consistent with findings in *Drosophila*^[@R6]^.

The temperature dependence of the canonical GAL4-UAS system and the optimal growth temperature of *S. cerevisiae* (30--34°C)^[@R6],[@R7]^ suggested that activity of Gal4p from a specific yeast species may be adapted to its optimal growth temperature. Thus, a Gal4p from more cryophilic *Saccharomyces* yeast species might prove useful in designing a more robust driver at lower temperatures. We chose the Gal4p DBD from *Saccharomyces kudriavzevii*^[@R8]^ (Portuguese reference strain ZP591, residues 1--147, henceforth GAL4~SK~) because *S. kudriavzevii* has an optimal growth temperature (23--24°C)^[@R7]^ close to that of *C. elegans* and the key residues necessary for UAS binding^[@R9]^ are conserved between GAL4~SC~ and GAL4~SK~ ([Fig. 2a](#F2){ref-type="fig"}).

We generated a new *Pmyo-2* driver by replacing GAL4~SC~ with GAL4~SK~, and compared its performance across 15--25°C using the same integrated *15xUAS::gfp* effector strain (*syIs300)*. The *Pmyo-2::GAL4~SK~::VP64* driver lines exhibited more fluorescence than the *Pmyo-2::GAL4~SC~::VP64* driver lines at room temperature; blinded researchers could accurately sort these two drivers using an epifluorescence dissecting microscope. We chose the brightest line from each for quantitation. At all temperatures, the *Pmyo-2::GAL4~SK~::VP64* driver performed more robustly than the *Pmyo-2::GAL4~SC~::VP64* driver, in some instances comparable to strains carrying a direct *Pmyo-2::gfp* fusion as a benchmark ([Fig. 2c](#F2){ref-type="fig"}; [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). Our GAL4~SK~ driver had slightly higher fluorescence at 25°C ([Fig. 2b--c](#F2){ref-type="fig"}), and exhibited only a \~20% drop at 20°C (versus \~67% for GAL4~SC~), and only a \~40% drop at 15°C (versus \~80% for GAL4~SC~). We adopted GAL4~SK~ as our DBD of choice, in conjunction with VP64 and 15xUAS, to comprise our fully optimized GAL4-UAS system. We designate it cGAL to denote its original implementation in *[C]{.ul}. elegans* and its engineered performance at [c]{.ul}ooler temperatures.

We tested whether cGAL would perform in other major tissues by generating new driver constructs containing various tissue-specific promoters (*Pnlp-40*, intestine; *Pmyo-3*, body wall muscles). When injected into a strain (*syIs300*) with an integrated *15xUAS::gfp* effector, these new drivers produced robust and specific GFP fluorescence in expected tissues ([Fig. 3a--b](#F3){ref-type="fig"}).

However, our initial pan-neuronal (*Prab-3*) and GABAergic (*Punc-47*) drivers displayed poor, mosaic expression in the nervous system along with intense ectopic GFP fluorescence in the posterior gut (data not shown). We speculated that our vector backbone (a derivative of pPD49.26 containing the *unc-54* 3'UTR) might be responsible. We therefore switched to the vector pPD117.01 containing the *let-858* 3'UTR and a 5' decoy sequence (comprising a decoy intron and ORF) upstream of the MCS (Methods; [Supplementary Note 1--2](#SD1){ref-type="supplementary-material"}); these modifications reduce ectopic expression and improve expression in a broad range of tissues (A. Fire, personal communication). We generated new *Prab-3* and *Punc-47* driver constructs in the pPD117.01 backbone and injected them into a strain (*syIs390*) with a new *15xUAS::gfp::let-858 3'UTR* effector (also made using pPD117.01; [Supplementary Note 3--4](#SD1){ref-type="supplementary-material"}). These strains not only showed decreased ectopic fluorescence in the posterior gut, but also dramatically increased expression in the entire nervous system or GABAergic neurons, respectively ([Fig. 3c--d](#F3){ref-type="fig"}; data not shown). Cholinergic (*Punc-17*) and glutamatergic (*Peat-4*) neuronal drivers gave similarly strong and specific results in the *syIs390* effector strain ([Fig. 3e--f](#F3){ref-type="fig"}). Thus, cGAL is robust across a variety of tissues and we recommend using the pPD117.01 vector for driver and effector construction.

We then applied cGAL to functional studies by examining the rhythmic defecation motor program (DMP), which contains three sequential muscle contractions^[@R10]^. The final enteric muscle contraction occurs when the intestine releases neuropeptide NLP-40, which binds its receptor AEX-2 on GABAergic neurons, triggering an expulsion event^[@R11],[@R12]^ ([Fig. 3g](#F3){ref-type="fig"}). We applied cGAL to confirm the site-of-action of *aex-2* in GABAergic neurons for expulsion. We generated an effector line (*syEx1444*) with *15xUAS::aex-2(+)* cDNA in the *aex-2(sa3)* background. This strain was then combined with a *Pnlp-40* driver, *Punc-47* driver, or *Pmyo-3* driver to create *aex-2(sa3)* mutants expressing *aex-2(+)* cDNA specifically in the intestine, GABAergic neurons, or body wall muscles, respectively.

In *aex-2(sa3)* mutants, expulsion was nearly eliminated. Only the presence of both GABAergic driver and *15xUAS::aex-2(+)* cDNA effector rescued the expulsion defect of *aex-2(sa3)* mutants; neither alone could ([Fig. 3h](#F3){ref-type="fig"}). Expression of *aex-2(+)* cDNA in either body wall muscles or intestine did not rescue ([Fig. 3h](#F3){ref-type="fig"}). These results recapitulate a study using conventional promoter-cDNA fusion transgenes^[@R12]^. Therefore, cGAL can be used for tissue-specific rescue experiments.

Next, we tested whether cGAL could be applied to gain-of-function experiments. Channelrhodopsin is a light-sensitive cation channel that depolarizes cells in the presence of all-*trans* retinal and blue light^[@R13]^. Activation of GABAergic neurons in *C. elegans* causes worms to adopt a flaccid, paralyzed state. We injected the GABAergic driver construct into a strain (*syIs341*) carrying an integrated *15xUAS::hChR2(H134R)::eyfp::let-858 3'UTR* effector to express channelrhodopsin specifically in GABAergic neurons. In the presence of all-*trans* retinal, animals were subjected to a three pulse train of 475 nm blue light. Each excitation caused immediate, limp paralysis only in animals possessing both GABAergic driver and effector, but not in animals with either component alone ([Fig. 3i](#F3){ref-type="fig"}, [Supplementary Video 1](#SD4){ref-type="supplementary-material"}--[2](#SD5){ref-type="supplementary-material"} and data not shown). cGAL thus confers the ability to control exogenous transgene expression to dissect neural circuits in *C. elegans*.

Lastly, we built a basic cGAL driver and effector toolkit ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}--[2](#SD3){ref-type="supplementary-material"}). For drivers, we constructed strains and constructs for major tissues, major neurotransmitter cell types, and some individual sensory neurons. For effectors, we have integrated strains for cell labeling (GFP, mKate2, GFP-H2B and mCherry-H2B), cell ablation (ICE), calcium indicator (GCaMP6s), neuronal activation (ChR2), neuronal inhibition (HisCl1) and synaptic inhibition (TeTx). All effectors are integrated and at least one line for each integrated effector was confirmed functional ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"} and [Supplementary Video 1](#SD4){ref-type="supplementary-material"}--[5](#SD8){ref-type="supplementary-material"}).

One limitation of cGAL is the absence of Gal80p, a negative regulatory component used to repress Gal4p as a 'NOT' gate^[@R14]^. Gal80p recognizes the C-terminus of Gal4p^[@R15]^, absent in our drivers. Addition of the minimal C-terminal functional domain that interacts with *S. kudriavzevii* Gal80p might address this issue.

A similar bipartite expression system, Q^[@R16]^, has yet to be widely adopted in C. *elegans*, perhaps due to lack of sufficient strains. As with *Drosophila*^[@R1],[@R17]^, the cGAL system could be combined with Q or other binary expression systems^[@R16],[@R18]--[@R20]^ for control of multiple effectors.

cGAL can already greatly facilitate genetic site-of-action and genome-wide overexpression experiments, but we envision that a growing collection of drivers and effectors will allow analysis of genetic, developmental, and neural networks with increased rate and rigor.

METHODS {#S1}
=======

Maintenance of *C. elegans* Strains {#S2}
-----------------------------------

Strains were maintained on NGM plates with *E. coli* OP50 as the food source at room temperature as originally described^[@R21]^, unless noted otherwise. Bristol strain N2 is the wild-type reference strain. The strains used in this study are detailed in the [Supplementary Note 5--6](#SD1){ref-type="supplementary-material"} and all the integrated drivers and effectors are listed in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

Molecular Biology {#S3}
-----------------

Plasmids were constructed by standard molecular cloning techniques with either restriction enzyme cleavage and DNA ligation or Gibson assembly using enzymes from New England Biolabs (Beverly, MA). The coding region of GAL4~SK~, residues 1--147 of Gal4p from *Saccharomyces kudriavzevii* (the Portuguese reference strain ZP591, a gift from C. T. Hittinger), was PCR amplified from genomic DNA using 5' primer ggaGCTAGCatgaagctgttgtcttcaatgg and 3' primer cggGAATTCcggcgatacactcaactgactttggc. The synthetic ScaI-17mer sequence (CGGAGTACTGTCCTCCG)^[@R22]^ was used for the UAS site and was placed upstream of the *pes-10* basal promoter in all effector constructs. All constructs were built in either the pSM1 vector (a gift from C. Bargmann), a derivative of pPD49.26, which contains the *unc-54* 3'UTR, or the vector pPD117.01 (a gift from A. Fire), which contains the *let-858* 3'UTR and a 5' decoy minigene upstream of the MCS for promoter insertion ([Supplementary Note 1--4](#SD1){ref-type="supplementary-material"} for vector maps and sequences). We generated effector constructs for cell labeling (GFP, mKate2, GFP-H2B and mCherry-H2B), cell ablation (ICE)^[@R23]^, calcium reporter (GCaMP6s)^[@R24]^, neuronal activation (ChR2)^[@R25]^, neuronal inhibition (HisCl1)^[@R26]^ and synaptic transmission blocking (TeTx)^[@R27]^. Other details about plasmids and oligos used in the study are documented in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}.

Transformation {#S4}
--------------

Transgenic animals were generated using standard microinjection techniques^[@R28]^. Unless noted otherwise, 100 ng/µL total DNA injection samples were prepared, with either the pBluescript II KS+ plasmid or 1 kb DNA ladder, from New England Biolabs (Beverly, MA), as carrier. Extrachromosomal arrays were integrated into the genome via X-ray irradiation. Most of the integrants were outcrossed at least three times with the wild type strain N2. Full details about transgenic *C. elegans* strains in this study are listed in the [Supplementary Note 5](#SD1){ref-type="supplementary-material"} and [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

Fluorescence Imaging {#S5}
--------------------

Approximately 25 animals per line were imaged and quantified for the optimization process of the cGAL system, using the *myo-2* promoter (*Pmyo-2*). Briefly, L4 or young adults animals grown at corresponding temperatures (15°C, 20°C, 25°C or room temperature) were selected and imaged with Leica DMI600 inverted microscope equipped with a 40× oil objective and an Andor iXon Ultra 897 EMCCD camera, using Metamorph software (Molecular Devices). Images were captured with the same exposure time (20 ms) and the average fluorescence in the pharynx for each animal was analyzed. The representative fluorescent images in [Fig. 3a--f](#F3){ref-type="fig"} showing the application of cGAL in different tissues were collected with a Zeiss LSM710 confocal microscope with a 20× objective.

Defecation Motor Program Assay {#S6}
------------------------------

L4 animals raised at room temperature were picked one day before the assay. During the assay, which was performed at 20°C, each individual worm was picked to a new NGM plate seeded with OP50 and an 18×18 mm coverslip was placed over the animal for better optics. After a two-minute acclimation period, each animal was videotaped using a Zeiss Stemi SV11 coupled to a Unibrain Fire-i 501b camera for five minutes and the number of pBoc and expulsion events were scored. Each pBoc indicated the initiation of each defecation cycle. The ratio of expulsions over pBocs was used to quantify the expulsion phenotype for each animal (n = 7--8 for each genotype).

Optogenetics {#S7}
------------

One day before the assay, L4 animals raised at room temperature from each strain were picked individually onto NGM plates, seeded with 100 µL OP50 containing 500 µM all-*trans* retinal (Sigma). During the assay, which was performed at 20°C, animals were recorded using a Zeiss Stemi SV11 coupled to a Unibrain Fire-i 501b camera. Channelrhodopsin was activated using blue light generated from a Lumen Dynamics X-Cite series 120 lamp and a standard GFP filter set. Blue 475 nm light intensity was measured to be 0.2 mW/mm^2^. After an initial 10-second acclimation period, three light pulses, each 2 seconds in duration, were delivered to each worm at intervals of 20 seconds. The researcher doing the assay was blinded to the genotype of the animals.

Histamine Chloride Inhibition {#S8}
-----------------------------

Histamine plates were made by adding histamine dihydrochloride (Sigma) to the standard NGM recipe for a final concentration of 10 mM. Animals were picked onto plates with a small amount of food. After 30 minutes, worms were recorded using a Zeiss Stemi SV11 coupled to a Unibrain Fire-i 501b camera.

Statistics {#S9}
----------

For all descriptions of number of animals 'n' used, numbers correspond to each column from left to right. All bars are mean ± SEM.

[Figure 1c](#F1){ref-type="fig"}: Two-sample Student's t-test with Welch's correction, as *the Pmyo-2::GAL4~SC~::VP16* strain displayed much smaller variance. n = 58, 50.

[Figure 1e](#F1){ref-type="fig"}: One-way ANOVA, with Tukey's post-test for multiple comparisons. n = 89, 58, 56, 60.

[Figure 2c](#F2){ref-type="fig"}: Two-way ANOVA, comparing genotype and temperature, with Tukey's post-test for multiple comparisons. n = 28, 22, 25, 26, 30, 30, 29, 27, 26.

[Figure 3h](#F3){ref-type="fig"}: One-way ANOVA, with Tukey's post-test for multiple comparisons. n = 8, 8, 8, 8, 8, 7, 7.

[Figure 3i](#F3){ref-type="fig"}: Mann-Whitney test. n = 20, 10.

Supplementary Material {#SM}
======================
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![Optimization of activation domain and UAS copy number\
(**a**) Schematic of the GAL4-UAS bipartite gene expression system. DBD: DNA-binding domain; AD: activation domain. Representative images (**b**) and quantification (**c**) of GFP fluorescence in animals carrying transgene arrays of VP16 or VP64 activation domains fused to the DBD of *S. cerevisiae* Gal4p, driving a *15xUAS:gfp* effector (*syIs300)* using the *Pmyo-2* pharyngeal muscle promoter. Two independent lines for each driver, n = 58, 50. Bars are mean ± SEM, \*\*\*\*p \< 0.0001, two-sample t-test with Welch's correction. Representative images (**d**) and quantification (**e**) of GFP fluorescence in animals carrying transgene arrays of varying UAS copy number on GFP effector constructs, driven by the same integrated *Pmyo-2::GAL4~SC~::VP64* driver (*syIs301*). 2--3 independent lines for each genotype, n = 89, 58, 56, 60, left to right. Bars are mean ± SEM. Scale bar is 20 µm. \*\* p \< 0.01 and \*\*\*p\<0.001. ns, not significant. One-way ANOVA with Tukey's post-test. a.u., artificial units.](nihms831958f1){#F1}

![Designing a temperature-robust GAL4 driver via evolutionary analysis\
(**a**) Alignment of the DNA binding domains (residues 1--147) of Gal4p sequences from *S. cerevisiae* (GAL4~SC~) and *S. kudriavzevii* (GAL4~SK~). Two critical UAS-interacting lysine residues are marked with red arrowheads. Six cysteines forming the conserved Zn~2~Cys~6~ binuclear cluster are marked with blue arrowheads. Asterisk (\*), colon (:), and period (.) indicate identical residues, strongly conserved residues and weakly conserved residues, respectively. Representative images (**b**) and quantification (**c**) of GFP fluorescence in animals carrying an integrated *15xUAS::gfp* effector (*syIs300*), injected with identical concentrations of *Pmyo-2::GAL4~SC~ ::VP64* (*syEx1434*) or *Pmyo-2::GAL4~SK~ ::VP64* (*syEx1436*) at 15°C, 20°C, and 25°C. A direct fusion *Pmyo-2::gfp* was assayed as a benchmark. Scale bar is 20 µm. n = 28, 22, 25, 26, 30, 30, 29, 27, 26, left to right. Bars are mean ± SEM. All pairwise comparisons at each temperature are significant except *Pmyo-2::GAL4~SK~::VP64* and *Pmyo-2::gfp* at 20°C, and *Pmyo-2::GAL4~SC~::VP64* and *Pmyo-2::gfp* at 25°C. Two-way ANOVA, Tukey's multiple comparison test. a.u., artificial units.](nihms831958f2){#F2}

![Functional studies with the cGAL system\
GFP effector expression in a variety of major tissues (**a--f**), each driven by the indicated cGAL driver. In (**c--f**), both driver and effector constructs (*15xUAS::gfp::let-858 3'UTR*) are built in the pPD117.01 vector. (**g**) The signaling pathway in the circuit controlling the final expulsion step in the defecation motor program. AEX-2 is necessary in two GABAergic neurons DVB and AVL (AVL not shown) to mediate expulsion. (**h**) Quantification of expulsion events per defecation cycle in animals with indicated genotypes. *aex-2* rescue experiments with GABAergic driver, *Punc-47*; muscle driver, *Pmyo-3*; intestinal driver, *Pnlp-40*. Bars are mean ± SEM. n = 8, 8, 8, 8, 8, 7, 7 from left to right. \*\*\*\* p\<0.0001. ns, not significant. One-way ANOVA with Tukey's post-test. (**i**) Quantification of paralysis in animals having channelrhodopsin (ChR2) specifically expressed in GABAergic neurons *(Punc-47 driver)* and exposed to blue light in the presence of all-trans retinal. Each dot represents mean response to three blue light exposures from an individual animal. Bars are mean ± SEM. n = 20 and 10, from left to right. \*\*\*\* p \< 0.0001, Mann-Whitney test.](nihms831958f3){#F3}
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